At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies.


T cells kill microbial-infected and malignant cells by detection of nonself antigens with the TCR. Tumor reactivity can be encoded genetically by introducing a chimeric antigen receptor (CAR) into T cells. CARs are composed of an antigen-binding domain and an intracellular T cell activation domain. Early human trials evaluating CD19-targeted CAR T cells for… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Blog articles referencing this paper